澳大利亚生物科技企业Noxopharm(NOX.AX)股价单日暴涨近46%至0.07澳元，创下去年10月4日以来最大单日涨幅。盘中股价触及6月6日以来最高点，此前该公司宣布自体免疫疾病候选药物SOF-SKN完成首例受试者给药。
市场交投热度骤增，当日成交量达422,086股，达到30日平均交易量的2.2倍。值得关注的是，尽管今日股价强势反弹，该股年内累计跌幅仍达24.7%。
SOF-SKN作为治疗自体免疫疾病的创新药物，其临床试验进展引发市场强烈反应。投资者密切关注该药物后续研发进程，这将成为影响企业估值走势的关键变量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.